Latest Cancer News
TUESDAY, Nov. 4, 2014 (HealthDay News) -- Patients with advanced melanoma may live longer when treated with a combination of the cancer drug Yervoy and the immune system booster sargramostim, a new study finds.
Patients given the two drugs had a median survival of 17.5 months, compared to 12.7 months for those on Yervoy (ipilimumab) alone. At one year, overall survival was nearly 69 percent for those on the combination therapy, versus 53 percent for those on Yervoy alone, the researchers said.
"Patients did live longer, as well as having less serious side effects, when given the combination," said lead researcher Dr. F. Stephen Hodi, an assistant professor of medicine at the Dana-Farber Cancer Institute in Boston.
Caught early, melanoma is treatable. And advances such as this one just reported, if replicated in future studies, could alter the bleak outlook for patients with melanoma that has spread, experts said.
Hodi believes that combination therapy has the potential for extending life in patients with this deadly disease.
"The future is really with combination therapies, how we combine targeted therapies, and the results of this trial suggest that the combination of sargramostim and ipilimumab should be part of that mix," Hodi said.
Melanoma might one day become a cancer people can live with, said Dr. Doris Day, a dermatologist at Lenox Hill Hospital in New York City.
Hodi said he doesn't know whether starting combination therapy before melanoma spreads will improve survival even more, but Day thinks it will.
"If patients are treated at diagnosis or after surgery, they may have a better outcome," Day said.
For this study -- published Nov. 5 in the Journal of the American Medical Association -- Hodi's team randomly assigned 245 patients with advanced melanoma to treatment with intravenous Yervoy alone or Yervoy plus injections of sargramostim.
While the dual-therapy group tended to live longer, both groups had similar time-to-disease progression -- a little more than three months, the study found.
Also, fewer patients on the drug combination suffered serious gastrointestinal problems, Hodi said.
"Overall, these are interesting results from a well-conducted, large phase 2 trial, but the field has moved so quickly that it may be difficult to follow up on the results," he said.
Either nivolumab or pembrolizumab (Keytruda) -- new drugs for advanced melanoma -- used alone will probably be more effective and less toxic, Sznol said. Also, early trial results suggest the combination of Yervoy and nivolumab will perform even better than the two evaluated in this study or either of the two newer drugs alone, he said.
"So these results, even if confirmed, are not as important as they would have been several years ago," Sznol said.
Copyright © 2014 HealthDay. All rights reserved.